Your browser doesn't support javascript.
loading
Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.
Nguyen, Teresa; Avci, Naze G; Shin, Dong Ho; Martinez-Velez, Naiara; Jiang, Hong.
Afiliación
  • Nguyen T; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 6767 Bertner St., Houston, TX 77030, USA. tnguyen36@mdanderson.org.
  • Avci NG; Neurosurgery Research, Houston Methodist Research Institute, Houston, TX 77030, USA. ngavci@houstonmethodist.org.
  • Shin DH; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 6767 Bertner St., Houston, TX 77030, USA. dshin4@mdanderson.org.
  • Martinez-Velez N; Pediatric Department, Clínica Universidad de Navarra, 31008 Pamplona, Spain. nmartinez.20@alumni.unav.es.
  • Jiang H; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 6767 Bertner St., Houston, TX 77030, USA. hjiang@mdanderson.org.
Cancers (Basel) ; 10(6)2018 May 31.
Article en En | MEDLINE | ID: mdl-29857493
With the progress of immunotherapy in cancer, oncolytic viruses (OVs) have attracted more and more attention during the past decade. Due to their cancer-selective and immunogenic properties, OVs are considered ideal candidates to be combined with immunotherapy to increase both specificity and efficacy in cancer treatment. OVs preferentially replicate in and lyse cancer cells, resulting in in situ autovaccination leading to adaptive anti-virus and anti-tumor immunity. The main challenge in OV approaches is how to redirect the host immunity from anti-virus to anti-tumor and optimize the clinical outcome of cancer patients. Here, we summarize the conceptual updates on oncolytic virotherapy and immunotherapy in cancer, and the development of strategies to enhance the virus-mediated anti-tumor immune response, including: (1) arm OVs with cytokines to modulate innate and adaptive immunity; (2) combining OVs with immune checkpoint inhibitors to release T cell inhibition; (3) combining OVs with immune co-stimulators to enhance T cell activation. Future studies need to be enforced on developing strategies to augment the systemic effect on metastasized tumors.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza